PROCEPT BioRobotics Co. (NASDAQ:PRCT) Director Sells $1,016,102.85 in Stock

PROCEPT BioRobotics Co. (NASDAQ:PRCT) Director Antal Rohit Desai sold 13,305 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $76.37, for a total value of $1,016,102.85. Following the transaction, the director now directly owns 317,518 shares in the company, valued at $24,248,849.66. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Antal Rohit Desai also recently made the following trade(s):

• On Tuesday, September 3rd, Antal Rohit Desai sold 35,220 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $76.12, for a total value of $2,680,946.40.

PROCEPT BioRobotics Stock Performance

Shares of PRCT traded up $0.33 on Thursday, reaching $76.35. 372,408 shares of the company’s stock traded hands, compared to its average volume of 592,971. The company has a current ratio of 7.51, a quick ratio of 6.49 and a debt-to-equity ratio of 0.20. The stock has a market cap of $3.96 billion, a PE ratio of -36.01 and a beta of 1.03. The stock’s 50 day simple moving average is $67.80 and its two-hundred day simple moving average is $60.17. PROCEPT BioRobotics Co. has a 52-week low of $24.83 and a 52-week high of $85.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.02. The company had revenue of $53.35 million during the quarter, compared to the consensus estimate of $50.10 million. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. PROCEPT BioRobotics’s revenue was up 61.2% on a year-over-year basis. During the same period last year, the business posted ($0.56) earnings per share. On average, analysts forecast that PROCEPT BioRobotics Co. will post -1.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning bought a new position in PROCEPT BioRobotics during the second quarter valued at $322,000. Algert Global LLC bought a new position in PROCEPT BioRobotics during the second quarter valued at $1,651,000. Driehaus Capital Management LLC grew its holdings in PROCEPT BioRobotics by 25.9% during the second quarter. Driehaus Capital Management LLC now owns 349,394 shares of the company’s stock valued at $21,344,000 after purchasing an additional 71,930 shares during the period. Lighthouse Investment Partners LLC grew its holdings in PROCEPT BioRobotics by 144.5% during the second quarter. Lighthouse Investment Partners LLC now owns 64,313 shares of the company’s stock valued at $3,929,000 after purchasing an additional 38,013 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new position in PROCEPT BioRobotics during the second quarter valued at $515,000. 89.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PRCT has been the subject of several analyst reports. Bank of America increased their price objective on PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Truist Financial increased their price objective on PROCEPT BioRobotics from $74.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Wells Fargo & Company increased their price objective on PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $74.17.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).